文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivo.

作者信息

Bonvicini Gillian, Singh Sunitha, Sandersjöö Lisa, Sehlin Dag, Syvänen Stina, Andersson Ken G

机构信息

BioArctic AB, Warfvinges Väg 35, 112 51, Stockholm, Sweden.

Department of Public Health and Caring Sciences/Geriatrics, Rudbeck Laboratory, Uppsala University, Dag Hammarskjölds Väg 20, 751 85, Uppsala, Sweden.

出版信息

Fluids Barriers CNS. 2025 Apr 8;22(1):36. doi: 10.1186/s12987-025-00643-y.


DOI:10.1186/s12987-025-00643-y
PMID:40200213
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11980351/
Abstract

BACKGROUND: Monovalent binding to the transferrin receptor (TfR) is considered the most efficient mode for high delivery of protein constructs across the blood-brain barrier via TfR-mediated transcytosis at therapeutic doses. However, growing evidence suggests this is not the case at lower, diagnostic doses. There is also a lack of data on how valency and affinity to TfR affect brain uptake independently since previous studies have not compared monovalent and bivalent antibodies with similar affinities regardless of valency (i.e. apparent affinity). Therefore, the aim was to evaluate the independent effects of valency and affinity on TfR-mediated brain delivery at different doses. METHODS: Affinity variants of antibody 8D3 were produced by introducing alanine point mutations into the complementarity-determining regions. Eleven Fab fragments and 29 IgGs were affinity screened against mouse TfR (mTfR). Six of each were chosen for production with a knob-into-hole design to have monovalent and bivalent TfR binders in full-length antibody format. The apparent affinity of these 12 antibodies were tested in an Sp2/0-Ag14 cell assay. The 10 nM apparent affinity set and the bivalent wild-type antibody were radiolabelled and injected into wild-type mice at a low (0.22 ± 0.03 mg/kg) or high (7.5 ± 0.43 mg/kg) dose. The biodistribution was measured in brain, blood and peripheral organs 4 h post-injection. RESULTS: Two sets of monovalent and bivalent 8D3 formats with similar mTfR apparent affinities were identified. Brain and tissue uptake was higher at the low dose than the high dose for all antibodies. At the low dose, the higher apparent affinity, bivalent antibody had higher brain uptake than either of the two lower apparent affinity antibodies. At the high dose, the monovalent antibody had higher brain uptake than the two bivalent antibodies. The peripheral distribution of the three antibodies were similar to the brain distribution at both doses. CONCLUSIONS: Valency and apparent affinity affect brain uptake in a dose-dependent manner such that: brain uptake was affected more by apparent affinity at the low dose and by valency at the high dose. Thus, when designing constructs for TfR-mediated brain delivery, the application, and consequently the dose, are critical to consider.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c3d/11980351/e51fd3ba6d76/12987_2025_643_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c3d/11980351/ea7df82783f2/12987_2025_643_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c3d/11980351/cd593f041a4a/12987_2025_643_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c3d/11980351/0a722ba57ba9/12987_2025_643_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c3d/11980351/05810fc879aa/12987_2025_643_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c3d/11980351/e51fd3ba6d76/12987_2025_643_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c3d/11980351/ea7df82783f2/12987_2025_643_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c3d/11980351/cd593f041a4a/12987_2025_643_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c3d/11980351/0a722ba57ba9/12987_2025_643_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c3d/11980351/05810fc879aa/12987_2025_643_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c3d/11980351/e51fd3ba6d76/12987_2025_643_Fig5_HTML.jpg

相似文献

[1]
The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivo.

Fluids Barriers CNS. 2025-4-8

[2]
A shorter linker in the bispecific antibody RmAb158-scFv8D3 improves TfR-mediated blood-brain barrier transcytosis in vitro.

Sci Rep. 2024-12-23

[3]
Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood-brain barrier in vitro is dependent on its binding affinity.

J Neurochem. 2018-8-16

[4]
Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26.

Mol Pharm. 2018-3-6

[5]
A single-chain fragment constant design enables easy production of a monovalent blood-brain barrier transporter and provides an improved brain uptake at elevated doses.

J Neurochem. 2023-5

[6]
Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor.

Theranostics. 2017-1-1

[7]
Lowering the affinity of single-chain monovalent BBB shuttle scFc-scFv8D3 prolongs its half-life and increases brain concentration.

Neurotherapeutics. 2025-1

[8]
Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants.

J Exp Med. 2014-1-27

[9]
Antibody affinity and valency impact brain uptake of transferrin receptor-targeted gold nanoparticles.

Theranostics. 2018-5-24

[10]
Study of the transcytosis of an anti-transferrin receptor antibody with a Fab' cargo across the blood-brain barrier in mice.

Eur J Pharm Sci. 2013-6-7

引用本文的文献

[1]
High-affinity transferrin receptor binding improves brain delivery of bispecific antibodies at tracer dose.

Fluids Barriers CNS. 2025-8-21

[2]
Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease.

J Prev Alzheimers Dis. 2025-9

本文引用的文献

[1]
Single domain antibody-scFv conjugate targeting amyloid β and TfR penetrates the blood-brain barrier and interacts with amyloid β.

MAbs. 2024

[2]
Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody.

MAbs. 2024

[3]
Comparing in vitro affinity measurements of antibodies to TfR1: Surface plasmon resonance versus on-cell affinity.

Anal Biochem. 2024-3

[4]
Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans.

MAbs. 2023

[5]
Enhanced in vivo blood brain barrier transcytosis of macromolecular cargo using an engineered pH-sensitive mouse transferrin receptor binding nanobody.

Fluids Barriers CNS. 2023-8-24

[6]
Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody.

Fluids Barriers CNS. 2023-5-11

[7]
Access to the CNS: Strategies to overcome the BBB.

Int J Pharm. 2023-4-5

[8]
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer's disease with a bispecific, brain-penetrating fusion protein.

Transl Neurodegener. 2022-12-26

[9]
Engineering antibody and protein therapeutics to cross the blood-brain barrier.

Antib Ther. 2022-11-9

[10]
Blood-Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles.

Pharmaceutics. 2022-10-19

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索